Arrowstreet Capital, Limited Partnership Cara Therapeutics, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$2.83 - $4.94 $565,688 - $987,456	199,890 New	199,890 $566,000
Q1 2021 May 14, 2021	SELL	$15.07 - $21.71 $418,946 - $603,538	-27,800 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$12.72 - $16.16 $68,688 - $87,264	-5,400 Reduced 16.27%	27,800 $421,000
Q3 2020 Nov 12, 2020	BUY	$12.34 - $17.92 $409,688 - $594,944	33,200 New	33,200 $422,000
Q1 2020 May 15, 2020	SELL	$9.12 - $17.78 $658,464 - $1.28 Million	-72,200 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$16.11 - $25.98 $1.16 Million - $1.88 Million	72,200 New	72,200 $1.16 Million
Q2 2019 Aug 14, 2019	SELL	$17.68 - $21.57 $387,050 - $472,210	-21,892 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$14.41 - $19.64 $315,463 - $429,958	21,892 New	21,892 $430,000

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $262M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.